23September

Novo Nordisk submits application in the US for including data from the two SWITC ... Read more

16September

NovoRapid® receives positive CHMP opinion for extended use in children as young ... Read more

16September

Semaglutide reduced major cardiovascular events by 26% in adults with type 2 dia ... Read more

15September

Victoza® lowered the progression of kidney damage in adults with type 2 diabetes ... Read more

23September

Novo Nordisk submits application in the US for including data from the two SWITC ... Read more

19September

Novo Nordisk A/S - Share repurchase programme ... Read more

12September

Novo Nordisk A/S - Share repurchase ... Read more

05September

Novo Nordisk A/S - Share repurchase programme ... Read more

29September

JP Morgan Milan Investor Forum, Milan

02October

Silent period,

28October

Financial statement for the first nine months of 2016,

15November

Bryan Garnier European Healthcare Conference,

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
EASD investor presentation
 
Q2 financial results


Access the Q2 conference call and material



Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



IR material


Download relevant Investor Relations material



Contacts



Subscriptions


Sign up to receive company announcements.



Annual Report 2015


Download the Novo Nordisk Annual Report 2015